Thursday, March 09, 2017 7:08:48 PM
Celgene, the buyer, spoke at a conference recently suggesting they expect that drug to sell in the $4-6 billion area.
It has been published that the market for the Innate drug is $7 billion and there is no other drug for SPMS. If, for example, the drug got a 50% market share plus there is use for the drug in the cancer arena as also published (ovarian cancer was mentioned in an article I read) we could be looking at sales at a similar size to the Receptos/Celgene drug, don't you think ?
Take $7.2 billion into around 250,000,000 shares and you have a very happy pay day. Who knows what will happen but I'd welcome other opinions.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM